Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Invitation Accepted: Biopharma Leaders Will Testify At Senate Hearing On Pricing

Executive Summary

In addition to fielding tough questions about pricing practices at the session, executives may announce new voluntary efforts to lower drug costs and will offer their own ideas for legislation.


Related Content

Ways And Means Drug Pricing Hearing Emphasizes Repetitive, Years-Old Questions
Big Pharma CEOs Get Ready To Testify: Preparing For A No-Win Situation
REMS Abuse Website: Has It Changed The Behavior Of Innovators?
HHS Rebate Plan A Leap Of Faith? Lower Costs Hinge On Drug Firm, Plan Response
Sen. Grassley To Be "More Insistent" About Drug Firms' Testimony At Future Hearings
Trulicity DTC Ads Reference Lilly Website For List Price, Cost Sharing Info
DTC Ad Proposal: Biopharma, Advertisers Marshall Legal Arguments In Opposition
340B Legislative Reforms: Where Do We Go From Here?
Biosimilar Humira Blocked Until 2023, But Time Could Clear Commercial Path
Brands Push Back Against REMS Reform, Call Problem Small With Burdensome Fixes


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts